510(k) Report

510(k) · Cleared

Cleared

NR Recorder

K161062510(k) TraditionalCleared Jun 13, 201659-day reviewClass II21 CFR 870.2800

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Norav Medical GmbH · MWJ Electrocardiograph, Ambulatory (Without Analysis)

Cleared on Jun 13, 2016 after a 59-day review. FDA’s file for it is a 510(k) statement, which names no predicate.

Decided
Jun 13, 2016
Review
59 days
Class
Class II
Product code
MWJ
Recalls
None
Predicates
0

FDA’s file for it is a 510(k) statement, which names no predicate.

FIG. 1 — Lineage of K161062Source: FDA 510(k) database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MWJ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new MWJ device

  1. #1 K254119 Wearable ECG Recorder (YMHeart XY-12)…score 14.1 · 8 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All MWJ devices

MWJ Electrocardiograph, Ambulatory (Without Analysis): FDA decisions, review times, recalls and adverse event reports over 20 years. 2016, this device’s year, is highlighted.

FDA decisions per year · MWJ

2in 2024

2007: 52008: 12009: 22010: 32011: 32012: 12013: 32014: 22016: 22018: 12021: 12022: 42024: 22026 (partial year): 5
2007high 5 (2007) · low 0 (2015)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MWJ

337in 2022

2007: 142 days median2010: 90 days median2011: 206 days median2013: 241 days median2022: 337 days median2026 (partial year): 270 days median
2007high 337 (2022) · low 90 (2010)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · MWJ

2in 2024

2024: 2
2007high 2 (2024) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · MWJ

8in 2025

2009: 52012: 22013: 42014: 12015: 12016: 12017: 22018: 12019: 42020: 122021: 32022: 62023: 52024: 32025: 8
2007high 12 (2020) · low 0 (2007)2025

MAUDE reports naming product code MWJ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
2007514200
20081—00
20092—05
201039000
2011320600
20121—02
2013324104
20142—01
20150—01
20162—01
20170—02
20181—01
20190—04
20200—012
20211—03
2022433706
20230—05
20242—23
20250—08
202652700—

What is it indicated for?

The NR recorder is intended for patients requiring: • Ambulatory (Holter) monitoring • Use within the physician office setting by the medical professional - Resting ECG monitoring (using Bluetooth communication) - Telemetry ECG monitoring (using Bluetooth communication) Such monitoring is most frequently used for the indications below: • Evaluation of symptoms suggesting arrhythmia or myocardial ischemia • Evaluation of ECG documenting therapeutic…

Read the full statement (125 words)

The NR recorder is intended for patients requiring:

• Ambulatory (Holter) monitoring

• Use within the physician office setting by the medical professional

- Resting ECG monitoring (using Bluetooth communication)

- Telemetry ECG monitoring (using Bluetooth communication)

Such monitoring is most frequently used for the indications below:

• Evaluation of symptoms suggesting arrhythmia or myocardial ischemia

• Evaluation of ECG documenting therapeutic interventions in individual patients or groups of patients

• Evaluation of patients for ST segment changes

• Evaluation of a patient's response after resuming occupational or recreational activities (for example, after myocardial infarction or cardiac surgery)

• Clinical and epidemiological research studies

• Evaluation of patients with pacemakers

• Reporting of time and frequency domain heart rate variability

• Reporting of QT interval

Indications for use as stated in the FDA 510(k) statement.

Cite this page

510(k) Report. “K161062: NR Recorder.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K161062

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Page last updated Nov 3, 2026